Hong Kong Stocks Movement | JACOBIO-B (01167) Rises Over 5% as Company Reports Preclinical Data for Inhibitor JAB-23E73

Stock News

Oct 27, 2025

JACOBIO-B (01167) saw an early morning increase of over 5%, climbing 5.32% to HKD 7.52, with a trading volume of HKD 41.58 million. The company announced that from October 22 to October 26, 2025, it presented its preclinical data for the orally bioavailable, potent pan-KRAS inhibitor JAB-23E73 at the 2025 American Association for Cancer Research (AACR) International Molecular Targets and Cancer Therapeutics Conference held at the Hynes Convention Center in Boston, Massachusetts. Notably, JACOBIO previously disclosed that it has signed a capital increase and equity transfer agreement with Haisong Capital and an industry partner, where Haisong Capital will acquire 80% of JACOBIO's subsidiary, JACORINKANG, for an initial payment of RMB 125 million and a milestone payment of RMB 75 million. Following this transaction, JACOBIO's ownership in JACORINKANG will decrease to 10%. This strategic divestment of non-core assets will enable the company to concentrate more on the oncology field while also bolstering its cash flow.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1118406799"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1118406799\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1118406799?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-27 11:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1118406799","market":"hk","top_or_hot":-1,"title":"Hong Kong Stocks Movement | JACOBIO-B (01167) Rises Over 5% as Company Reports Preclinical Data for Inhibitor JAB-23E73","media":"Stock News","content":"<p>JACOBIO-B (01167) saw an early morning increase of over 5%, climbing 5.32% to HKD 7.52, with a trading volume of HKD 41.58 million. The company announced that from October 22 to October 26, 2025, it presented its preclinical data for the orally bioavailable, potent pan-KRAS inhibitor JAB-23E73 at the 2025 American Association for Cancer Research (AACR) International Molecular Targets and Cancer Therapeutics Conference held at the Hynes Convention Center in Boston, Massachusetts. Notably, JACOBIO previously disclosed that it has signed a capital increase and equity transfer agreement with Haisong Capital and an industry partner, where Haisong Capital will acquire 80% of JACOBIO's subsidiary, JACORINKANG, for an initial payment of RMB 125 million and a milestone payment of RMB 75 million. Following this transaction, JACOBIO's ownership in JACORINKANG will decrease to 10%. This strategic divestment of non-core assets will enable the company to concentrate more on the oncology field while also bolstering its cash flow.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong Stocks Movement | JACOBIO-B (01167) Rises Over 5% as Company Reports Preclinical Data for Inhibitor JAB-23E73</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong Stocks Movement | JACOBIO-B (01167) Rises Over 5% as Company Reports Preclinical Data for Inhibitor JAB-23E73\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-10-27 11:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>JACOBIO-B (01167) saw an early morning increase of over 5%, climbing 5.32% to HKD 7.52, with a trading volume of HKD 41.58 million. The company announced that from October 22 to October 26, 2025, it presented its preclinical data for the orally bioavailable, potent pan-KRAS inhibitor JAB-23E73 at the 2025 American Association for Cancer Research (AACR) International Molecular Targets and Cancer Therapeutics Conference held at the Hynes Convention Center in Boston, Massachusetts. Notably, JACOBIO previously disclosed that it has signed a capital increase and equity transfer agreement with Haisong Capital and an industry partner, where Haisong Capital will acquire 80% of JACOBIO's subsidiary, JACORINKANG, for an initial payment of RMB 125 million and a milestone payment of RMB 75 million. Following this transaction, JACOBIO's ownership in JACORINKANG will decrease to 10%. This strategic divestment of non-core assets will enable the company to concentrate more on the oncology field while also bolstering its cash flow.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1118406799","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1118406799","pubTimestamp":1761535933,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"JACOBIO-B (01167) saw an early morning increase of over 5%, climbing 5.32% to HKD 7.52, with a trading volume of HKD 41.58 million. The company announced that from October 22 to October 26, 2025, it...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","01167":"加科思-B","BK1574":"生物医药B类股"},"translate_title":"港股动向|雅可比-B(01167)涨超5%公司公布抑制剂JAB-23E73临床前数据","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01167":1},"content_text":"JACOBIO-B (01167) saw an early morning increase of over 5%, climbing 5.32% to HKD 7.52, with a trading volume of HKD 41.58 million. The company announced that from October 22 to October 26, 2025, it presented its preclinical data for the orally bioavailable, potent pan-KRAS inhibitor JAB-23E73 at the 2025 American Association for Cancer Research (AACR) International Molecular Targets and Cancer Therapeutics Conference held at the Hynes Convention Center in Boston, Massachusetts. Notably, JACOBIO previously disclosed that it has signed a capital increase and equity transfer agreement with Haisong Capital and an industry partner, where Haisong Capital will acquire 80% of JACOBIO's subsidiary, JACORINKANG, for an initial payment of RMB 125 million and a milestone payment of RMB 75 million. Following this transaction, JACOBIO's ownership in JACORINKANG will decrease to 10%. This strategic divestment of non-core assets will enable the company to concentrate more on the oncology field while also bolstering its cash flow.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}